Observing the behavioural effects of methylphenidate in children and adolescents with ASD-ADHD dual diagnosis: A mini review.

Frontiers in child and adolescent psychiatry Pub Date : 2023-03-17 eCollection Date: 2023-01-01 DOI:10.3389/frcha.2023.1052115
Danilo Dimitri, Giuliana Delia, Maurizio Arduino, Nazarena Turco, Franco Fioretto
{"title":"Observing the behavioural effects of methylphenidate in children and adolescents with ASD-ADHD dual diagnosis: A mini review.","authors":"Danilo Dimitri, Giuliana Delia, Maurizio Arduino, Nazarena Turco, Franco Fioretto","doi":"10.3389/frcha.2023.1052115","DOIUrl":null,"url":null,"abstract":"<p><strong>Research aim: </strong>The aim of this study is to focus on the main neurophysiological aspects of attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) and the current pharmacological treatment used for the management of hyperactivity and attention deficits in children aged 6-20 years with a diagnosis of ASD, not associated with other genetic or epileptic disorders, such as Fragile X Syndrome (FXS), Tuberous Sclerosis, Kleefstra Syndrome or Angelman Syndrome.</p><p><strong>Methods: </strong>This mini review was conducted according to the <i>P</i>.I.C.O. model and according to the PRISMA guidelines. The keywords used were: <i>autism spectrum disorder</i>; <i>attention deficit hyperactivity disorder</i>; <i>attention deficit disorder</i>; <i>methylphenidate</i>; <i>ritalin</i>; <i>ADHD</i>; <i>youth autism</i>; <i>childhood autism</i>; <i>childhood autism spectrum disorder</i>; <i>adolescent autism</i>. The strings produced were compared and selected by a third independent clinician. The PubMed and PsycArticles search yielded a total of 3,200 articles. For their inclusion, the 3,200 articles were examined by two clinicians who ultimately selected 28 (15 clinical trials and 13 reviews/meta-analyses) articles analysed according to their consistency with the inclusion and exclusion criteria.</p><p><strong>Conclusions: </strong>Three main aspects emerged from the review: (1) According to the existing literature, new randomized controlled trials are needed to ensure a better understanding of the most effective drug treatments for dual-diagnosed ASD-ADHD patients and of the related behavioural effects. Currently, the use of drugs varies depending on psychiatric comorbidity, symptoms, age and gender and there is no univocal reference therapy; (2) Methylphenidate (MPH) has currently been shown to be the most suitable drug for the treatment of hyperactivity and inattention in individuals diagnosed with ASD and ADHD; (3) There is a need to create and evaluate appropriate tests to analyse more specific patterns of behaviour presented in the two conditions.</p>","PeriodicalId":73074,"journal":{"name":"Frontiers in child and adolescent psychiatry","volume":"58 1","pages":"1052115"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732115/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in child and adolescent psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/frcha.2023.1052115","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Research aim: The aim of this study is to focus on the main neurophysiological aspects of attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) and the current pharmacological treatment used for the management of hyperactivity and attention deficits in children aged 6-20 years with a diagnosis of ASD, not associated with other genetic or epileptic disorders, such as Fragile X Syndrome (FXS), Tuberous Sclerosis, Kleefstra Syndrome or Angelman Syndrome.

Methods: This mini review was conducted according to the P.I.C.O. model and according to the PRISMA guidelines. The keywords used were: autism spectrum disorder; attention deficit hyperactivity disorder; attention deficit disorder; methylphenidate; ritalin; ADHD; youth autism; childhood autism; childhood autism spectrum disorder; adolescent autism. The strings produced were compared and selected by a third independent clinician. The PubMed and PsycArticles search yielded a total of 3,200 articles. For their inclusion, the 3,200 articles were examined by two clinicians who ultimately selected 28 (15 clinical trials and 13 reviews/meta-analyses) articles analysed according to their consistency with the inclusion and exclusion criteria.

Conclusions: Three main aspects emerged from the review: (1) According to the existing literature, new randomized controlled trials are needed to ensure a better understanding of the most effective drug treatments for dual-diagnosed ASD-ADHD patients and of the related behavioural effects. Currently, the use of drugs varies depending on psychiatric comorbidity, symptoms, age and gender and there is no univocal reference therapy; (2) Methylphenidate (MPH) has currently been shown to be the most suitable drug for the treatment of hyperactivity and inattention in individuals diagnosed with ASD and ADHD; (3) There is a need to create and evaluate appropriate tests to analyse more specific patterns of behaviour presented in the two conditions.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
观察哌甲酯对儿童和青少年ASD-ADHD双重诊断的行为影响:一个小回顾。
研究目的:本研究的目的是关注注意力缺陷/多动障碍(ADHD)和自闭症谱系障碍(ASD)的主要神经生理学方面,以及目前用于管理6-20岁诊断为ASD的儿童多动和注意缺陷的药物治疗,这些儿童与其他遗传或癫痫性疾病(如脆性X综合征(FXS)、结节性硬化症、Kleefstra综合征或Angelman综合征)无关。方法:根据P.I.C.O.模型和PRISMA指南进行回顾性研究。使用的关键词是:自闭症谱系障碍;注意缺陷多动障碍;注意缺乏症;哌醋甲酯;利他林;多动症;青春自闭症;儿童孤独症;儿童自闭症谱系障碍;青少年自闭症。产生的字符串由第三个独立的临床医生进行比较和选择。PubMed和PsycArticles搜索总共产生了3200篇文章。为了纳入,两位临床医生对3200篇文章进行了检查,他们最终选择了28篇(15篇临床试验和13篇综述/荟萃分析)文章,根据它们与纳入和排除标准的一致性进行了分析。结论:综述总结了三个主要方面:(1)根据现有文献,需要开展新的随机对照试验,以确保更好地了解双重诊断的ASD-ADHD患者最有效的药物治疗方法及其相关的行为效应。目前,药物的使用因精神合并症、症状、年龄和性别而异,没有统一的参考治疗;(2)哌醋甲酯(MPH)目前已被证明是治疗ASD和ADHD患者多动和注意力不集中的最合适药物;(3)有必要建立和评价适当的测试,以分析在这两种情况下出现的更具体的行为模式。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
School attendance matters: co-occurring trajectories of school attendance and academic achievement from elementary to secondary school in a Canadian context. Commentary: Framing chronic absenteeism and emotionally based school absenteeism as public health problems. The neuroesthetics of music as an alternative therapeutic model for enhancing youth mental wellbeing. Correction: Mothers' eating disorder history and mother and infant attention to food during infant meal times: a candidate for intergenerational transmission of eating disorder behaviours. Genetic variability and response to sertraline in pediatric populations: a review on pharmacogenetics, pharmacokinetics, and the risk of adverse events.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1